Precigen: PAPZIMEOS takes off – $2 billion opportunity gains momentum
Reading Time: 3 minutes
Precigen sees global peak sales potential for PAPZIMEOS of more than $2 billion and holds market exclusivity in the U.S. until August 2032. PAPZIMEOS revenue soared by 146% in Q2 to $53.1 million, leading Precigen to quarterly profitability. Riley sees approximately 40% upside potential, while the P/E ratio for 2027 based on current estimates stands at around 13. Precigen (PGEN) develops immunotherapies. The focus is on PAPZIMEOS, which has been the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
